Autopsy report · NCT05127122

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS

“Change in development plan”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Direct Biologics, LLC

Sponsor type

Industry

Conditions

ARDS, Human

Interventions

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles; Saline

Participants

0

Trials that died the same way

• A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
  “Development plan change” (97% match in meaning)
• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (77% match in meaning)
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (75% match in meaning)
• A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
  “change in company plans” (75% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.